Molecular Profile Detail

Profile Name EZH2 F120L EZH2 Y111N
Gene Variant Detail

EZH2 F120L (unknown)

EZH2 Y111N (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
EZH2 F120L EZH2 Y111N Advanced Solid Tumor resistant Tazemetostat Preclinical - Cell culture Actionable In a preclinical study, a cancer cell line co-expressing EZH2 F120L and EZH2 Y111N was resistant to Tazemetostat (EPZ-6438) in culture, demonstrating no inhibition of cell proliferation (PMID: 28135235). 28135235
EZH2 F120L EZH2 Y111N diffuse large B-cell lymphoma resistant EI1 Preclinical - Cell culture Actionable In a preclinical study, diffuse large B-cell lymphoma cells co-expressing EZH2 F120L and EZH2 Y111N were resistant to EI1 in culture, demonstrating no inhibition of cell proliferation (PMID: 28135235). 28135235
EZH2 F120L EZH2 Y111N diffuse large B-cell lymphoma sensitive EED226 Preclinical - Cell culture Actionable In a preclinical study, diffuse large B-cell lymphoma cells co-expressing EZH2 F120L and EZH2 Y111N were sensitive to EED226, demonstrating inhibition of cell proliferation in culture (PMID: 28135235). 28135235
Clinical Trial Phase Therapies Title Recruitment Status